earnings
confidence high
sentiment positive
materiality 0.65
Matinas BioPharma reports Q3 net loss $6.1M; FDA supports MAT2203 Phase 3 with LPAD pathway
Matinas BioPharma Holdings, Inc.
2023-Q3 EPS reported
-$0.08
revenue$1,096,000
- Net loss of $6.1M ($0.03 per share) in Q3 2023 vs $5.5M in Q3 2022; no revenue vs $1.1M from BioNTech in prior year.
- Cash $18.2M at Sep 30, 2023; runway into Q3 2024; seeking non-dilutive BARDA funding.
- FDA agreed MAT2203 Phase 3 design for invasive aspergillosis with limited treatment options; acknowledged LPAD registration pathway.
- FDA open to superiority composite endpoint to strengthen commercial positioning without increasing study size (<200 patients).
- Patient with Candida krusei achieved complete clinical resolution after 2 weeks on MAT2203; new fusarium patient enrolled at Vanderbilt.